Last reviewed · How we verify
TSR-042
At a glance
| Generic name | TSR-042 |
|---|---|
| Also known as | Dostarlimab |
| Sponsor | Tesaro, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Anemia
- Constipation
- Decreased lymphocytes
- Decreased sodium
- Increased alkaline phosphatase
- Decreased albumin
- Sepsis
- Acute kidney injury
- Urinary tract infection
Key clinical trials
- Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma (PHASE2)
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery (PHASE2)
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (PHASE3)
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors (PHASE2)
- Dostarlimab and Cobolimab in Advanced Cervical Cancer (PHASE2)
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TSR-042 CI brief — competitive landscape report
- TSR-042 updates RSS · CI watch RSS
- Tesaro, Inc. portfolio CI